Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:24 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1589
Shown on this page
12
Current sort
Recently updated
Campus scope
Ohio State University Wexner Medical Center, Columbus, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Ohio State University Wexner Medical Center, Columbus, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 697–708 of 1,589 matching trials with a site at Ohio State University Wexner Medical Center, Columbus, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Ceralasertib, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Irvine, California • Los Angeles, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 1Phase 2 Interventional

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

NCT07012031
Status at this site: Recruiting
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 2 Interventional

Third Party Viral Specific T-cells (VSTs)

NCT02532452
Status at this site: Recruiting
View directory record Official record
Conditions
Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Interventions
Viral Specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Days and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
4
States / cities
Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting No phase listed Observational

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

NCT04239573
Status at this site: Recruiting
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
50 Years to 75 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
413
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Active, not recruiting Phase 3 Interventional

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

NCT04340141
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
441
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Active, not recruiting No phase listed Observational

A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot

NCT06879912
Site status not listed — check the official record
View directory record Official record
Conditions
Hernia, Inguinal, Hernia, Ventral, Colorectal, Thoracic, Gynecologic, Partial Nephrectomy
Interventions
Not listed
Lead sponsor
Intuitive Surgical
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Active, not recruiting Not applicable Interventional

Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

NCT04254185
Site status not listed — check the official record
View directory record Official record
Conditions
Neuropathy Ulnar
Interventions
Simple decompression, Subcutaneous anterior transposition
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Atlanta, Georgia • Louisville, Kentucky • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women

NCT07802054
Site status not listed — check the official record
View directory record Official record
Conditions
Communication, Message Perception, Alcohol, Cancer Prevention, Behavior, Risk
Interventions
Risk Message, Efficacy Message, Industry Deception, YAW Susceptibility, Mechanisms
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Early Phase 1 Interventional

ENDOTRACHEAL Tube LIDOCAINE

NCT07709390
Status at this site: Recruiting
View directory record Official record
Conditions
Emergency Coughing
Interventions
5% Lidocaine Ointment, Water-Based Lubricant
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 90 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 2 Interventional

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

NCT06567743
Status at this site: Recruiting
View directory record Official record
Conditions
High-Risk Non-Muscle-Invasive Bladder Cancer
Interventions
Cretostimogene Grenadenorepvec
Drug
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
79
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Active, not recruiting Phase 2 Interventional

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

NCT04699838
Site status not listed — check the official record
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
Cisplatin, Carboplatin, Etoposide, Durvalumab, Ceralasertib
Drug
Lead sponsor
Muhammad Furqan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 12:24 PM EST
Recruiting Phase 3 Interventional

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953
Status at this site: Recruiting
View directory record Official record
Conditions
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Interventions
Ivosidenib, Azacitidine
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 12:24 PM EST

About this Ohio State University Wexner Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.